Latest News

Researchers, led by Thazin Nwe Aung, PhD, in the laboratory of David Rimm, MD, PhD, have developed a way to predict how lung cancer cells will respond to different therapies, allowing people with the most common form of lung cancer to receive more effective individualized treatment.

An intensive two-day Yale Cancer Research symposium, dedicated to advancing cancer science through innovation and strengthening partnerships between Yale University and Historically Black Colleges and Universities (HBCUs), brought together researchers from multiple disciplines this week.

Regarding finding the right drug for the right patient, the reality of cancer management is far more complex than a single genetic mutation, according to David Rimm, MD, PhD.

It may be time for precision medicine to expand beyond the genomics realm and enter the protein space in the management of melanoma and other cancers, according to David Rimm, MD, PhD.

Dr. David Rimm spoke with Cancer Network on his latest research.

David Rimm, MD, PhD, Anthony N. Brady Professor of Pathology and professor of medicine at Yale School of Medicine, discussed two important developments to come out of his lab.

Yale Cancer Center researchers are trying to figure out if artificial intelligence can help people with cancer. They found that AI-based scoring of melanoma tumor-infiltrating immune cells, significantly outperforms traditional pathologist eyeballing.

Yale Cancer Center researcher David Rimm, MD, PhD, who is the Anthony N. Brady Professor of Pathology, and colleagues developed a novel assay to measure HER2 and TROP2 levels in patients with breast cancer. These data could help physicians decide which antibody-drug conjugates should be used in each individual case.